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Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), using gadopentetate dimeglumine, was used to monitor acute
effects on tumour vascular permeability following inhibition of vascular endothelial growth factor-A (VEGF-A) signal transduction.
Mice bearing PC-3 human prostate adenocarcinoma xenografts were treated with ZD6474, a VEGF receptor-2 (KDR) tyrosine
kinase inhibitor. The pharmacokinetic parameter K
trans was obtained, which reflects vascular permeability and perfusion. Mice were
imaged immediately before, and following, acute treatment with ZD6474 (12.5–100mgkg
 1 orally). Whole tumours were analysed
to obtain mean K
trans values, and a histogram approach was used to examine intratumour heterogeneity. Reproducibility of K
trans
measurements gave inter- and intra-animal coefficients of variation of 40 and 18%, respectively. Dose-related reductions in K
trans
were evident following acute ZD6474 treatment. A K
trans reduction of approximately 30% (Po0.001) was evident with 50 and
100mgkg
 1 ZD6474, a reduction of 12.5% (Po0.05) at 25mgkg
 1, and a reduction that did not reach statistical significance at
12.5mgkg
 1. A correlation between this dose response and the growth inhibitory effect of ZD6474 following chronic treatment was
also observed. The histogram analysis of the data indicated that ZD6474-induced a K
trans reduction in both the most enhancing rim
and the core of PC-3 tumours. Dynamic contrast-enhanced magnetic resonance imaging may have a role in assessing the acute effects
of VEGF signalling inhibition, in clinical dose-ranging studies.
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Vascular endothelial growth factor-A (VEGF) has a key role in
inducing the pathological angiogenesis required to sustain solid
tumour growth. Vascular endothelial growth factor-A expression is
elevated in tumours in response to a variety of stimuli (Rak et al,
1995; Dibbens et al, 1999; Igarashi et al, 2002), and its activity is
largely restricted to vascular endothelial cells via two high-affinity
receptors, Flt-1 (VEGF-R1) and KDR/Flk-1 (VEGF-R2). There are
data to suggest that activation of KDR alone is sufficient to
promote endothelial cell migration, proliferation and tubule
formation (Meyer et al, 1999; Gille et al, 2001; Zeng et al, 2001).
In addition to its proangiogenic effects on endothelial cells,
VEGF has a profound permeabilising effect on the vasculature and
increases vasodilation (Bates et al, 2002; Dafni et al, 2002), which
may also contribute to disease progression by enhancing tumour
nutrient and waste exchange. In keeping with other VEGF-induced
phenotypes, VEGF-dependent vascular permeability is also
thought to be contingent on activation of KDR. This dependency
is suggested by studies that have employed ligands with differential
selectivity for KDR vs Flt-1 (Joukov et al, 1998; Ogawa et al, 1998;
Gille et al, 2001; Hillman et al, 2001) or KDR-blocking antibodies
(Wu et al, 1999; Brekken et al, 2000). Recently, placental growth
factor (PlGF), a selective Flt-1 ligand, has been shown to enhance
the vascular permeabilising effect of VEGF (Carmeliet et al, 2001;
Luttun et al, 2002). However, it is conceivable that this
phenomenon may involve a cooperative effect with KDR, either
via cross receptor signalling, or by PlGF displacement of VEGF
already bound to Flt-1, thereby increasing the VEGF that is
accessible for binding to KDR.
A number of mechanism-based approaches to inhibit VEGF
signal transduction are currently in clinical development. Each of
these strategies is likely to require protracted dose administration
to prevent angiogenesis and suppress tumour growth. Since
disease stabilisation, or increased time to progression, is an
anticipated therapeutic outcome, biological markers of activity are
being sought to provide dose–response information earlier in the
course of treatment. In this regard, imaging methodologies are an
attractive prospect, given their noninvasive nature and the
potential to provide functional information (Libutti et al, 1999).
In particular, dynamic contrast-enhanced magnetic resonance
imaging (DCE-MRI), where the uptake and washout of a contrast
agent in tissues is monitored with time, can provide physiological
information on vascular permeability, volume of interstitial space
and perfusion. Computed tomography (CT) has also been used in
this way (Miles, 2002), although, in contrast to DCE-MRI, the
frequency with which CT can be used is restricted by the
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laccumulative dose of radiation that can be administered safely.
While DCE-MRI may not be applicable to all antiangiogenic
approaches, it could be amenable to monitoring VEGF signalling
inhibition, given that VEGF can render tumour vessels hyper-
permeable.
ZD6474 is a novel, small molecular weight inhibitor of KDR
tyrosine kinase activity and VEGF-stimulated endothelial cell
proliferation in vitro (Hennequin et al, 2002). The compound is
active orally, is well tolerated following chronic administration and
produces significant inhibition of tumour growth in a range of
models in vivo (Wedge et al, 2002). Clinical evaluation of ZD6474
is currently ongoing in patients with a range of solid tumours
(Hurwitz et al, 2002). This study examined the ability of DCE-MRI
to measure permeability changes, following acute administration
of ZD6474 in a human PC-3 prostate tumour model. In order to
produce MRI measurements that were independent of machine
settings, data were analysed using a pharmacokinetic model, with
the transfer constant (K
trans) being measured as an indicator of
vascular permeability (Tofts et al, 1999). Although the majority of
preclinical DCE-MRI studies examining VEGF-signalling
inhibition have previously utilised albumin-gadopentetate dime-
glumine (Gd-DTPA) (Pham et al, 1998; Brasch et al, 2000;
Gossmann et al, 2000), there are no large molecular weight
contrast agents currently licensed for use in man. Low molecular
weight gadopentetate dimeglumine (Gd-DTPA) was therefore
employed because of its wide availability and established clinical
use. In contrast to other studies, a voxelwise multislice tumour
analysis was performed, rather than using small region of
interest (ROI) or single slice data. In addition, to avoid sampling
errors and enable exploration of intratumour heterogeneity,
both whole tumour mean values and histogram analyses were
examined.
The data indicate that significant reductions in K
trans can be
measured in PC-3 tumours following acute ZD6474 treatment.
Furthermore, the magnitude of the change in K
trans is dose-related
(12.5–50mgkg
 1 ZD6474) and can be correlated with the effect on
PC-3 tumour growth induced by more chronic ZD6474 treatment.
This study also highlighted the utility of using a histogram method
to analyse DCE-MRI data, with greater effects on K
trans being
evident in the core of the tumour.
MATERIALS AND METHODS
Xenograft model and antitumour studies
All in vivo studies were performed in full compliance with the UK
Animals (Scientific Procedures) 1986 Act. PC-3 human prostate
adenocarcinoma xenografts were established in athymic mice as
described previously (Wedge et al, 2000). Briefly, female Swiss
athymic mice, at least 8-weeks old, were injected subcutaneously
with 10
6 cells into the hind flank. Tumour volumes were estimated
from twice-weekly bilateral Vernier caliper measurements using
the formula (length width) O (length width) (p/6), taking
length to be the longest diameter across the tumour and width the
corresponding perpendicular. We have previously shown that
there is a good correlation between tumour volumes determined
by caliper and MRI measurement (Waterton et al, 1997), However,
an assessment of tumour volume by MRI was not employed in this
study because slice thickness (2mm) was large relative to the
tumour dimensions, and use of caliper measurements enabled a
direct comparison with volume estimates in chronic tumour
growth studies. Tumours reached a volume (mean7s.e.) of
1.2270.08cm
3 in MRI studies and 0.9870.04cm
3 in chronic
tumour growth studies, before mice were randomised into groups
and treated with ZD6474 or vehicle. ZD6474 was suspended in a
1% (vv
 1) solution of polyoxyethylene sorbitan monoleate in
deionised water and the animals were dosed once daily by oral
gavage at 0.1ml10
 1g body weight. In tumour growth studies,
ZD6474 or vehicle were administered once daily for 11 days.
MRI studies
The Tofts and Kermode model considers contrast moving
passively between two compartments; plasma and the extracellular
space (VE). The transfer constant for this movement (K
trans)i s
dependent on the blood flow, the surface area and the permeability
of the vasculature. The concentration of Gd-DTPA in plasma and
tissue is determined from the change in T1 relaxation and the
relaxivity of Gd-DTPA in plasma and tissue. The input function
measured in the abdominal aorta is assumed to be equivalent to
that in the tumour vasculature.
Three separate experiments were carried out that included
control groups given vehicle alone, and one or more treatment
groups given ZD6474 at 12.5, 25, 50 or 100mgkg
 1day
 1.
Dynamic contrast-enhanced magnetic resonance imaging was
performed twice, before and after treatment with ZD6474, with
the second DCE-MRI under terminal anesthesia. The treatment
regimen was two doses, given 24 and 2h prior to the second DCE-
MRI. Animals were anesthetised with 1–1.5% halothane
(‘Fluothane’, AstraZeneca, Macclesfield, UK) for approximately
2h during which they were mounted in a lidded plastic cradle
fitted with a thermocouple and electrocardiogram electrodes.
Under a flow of warm air, a heparinised 26-gauge catheter was
inserted into the tail vein and attached to a syringe containing
30mM Gd-DTPA (‘Magnevist’, Schering, Berlin, Germany) in
sterile water. The mice were then transferred, in the cradle, to
the bore of a horizontal magnet, where their temperature was
maintained at 38.070.51C by a flow of warm air, and their heart
rates were monitored.
MRI acquisition protocol
Dynamic contrast-enhanced magnetic resonance imaging was
carried out on an instrument incorporating a 63mm bore
quadrature birdcage coil and a 4.7Tesla horizontal-bore magnet
interfaced to a spectrometer (
UNITYInova, Varian Medical Systems,
Palo Alto, CA, USA). The precontrast acquisition protocol
comprised a heavily T2-weighted multislice fast spin-echo
sequence with a repetition time (TR) of 3000ms and an effective
echo time (TE) of 120ms. Four slices were obtained covering the
whole tumour volume with a resolution of 0.625 0.312 2mm
(this resolution was employed throughout with a matrix of
512 256 4). This was followed by a saturation-recovery
sequence for T1 mapping of the tumour that consisted of a series
of 4multislice spin-echo image sets (TR¼120, 500, 2000 and
10000ms; TE¼10ms). Repeated T1-weighted spin-echo imaging
(TR¼120ms, TE¼10ms) was then used to generate multislice
dynamic data. Spin-echo images were employed as opposed to the
faster gradient-echo, as spin-echo approaches are less prone to
confounds from radiofrequency inhomogeneity in assessment of
T1 changes than are gradient echoes. Spin -echoes were also found
to give a better signal-to-noise ratio and therefore increased the
accuracy of voxel by voxel data fitting. Following acquisition of
five dynamic data sets, Gd-DTPA solution (0.01mlg
 1 body
weight) was manually injected over 3s into the tail vein of the
animals. The dynamic run then continued with repetitions every
16s for 11min after the injection, providing 40 image sets. A
calibration curve was prepared by measuring the longitudinal
relaxation time (T1) of filtered mouse blood plasma solutions
containing different Gd-DTPA concentrations. The concentrations
ranged from 0.0–1.8mM and were measured at 381C using a
saturation-recovery spin-echo imaging sequence. The calibration
curve was used to obtain the relaxivity of Gd-DTPA. A vascular
input function, obtained previously in the same animal model, and
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½Gd 
plasma
t ¼ D½a1 expð m1tÞþa2 expð m2tÞ 
where D¼0.3mmolkg
 1, the bolus dose of Gd-DTPA; the terms
a1¼11.95kgl
 1 and m1¼0.0195 represent the equilibration of
Gd-DTPA between plasma and extracellular space; m2¼0.0009
reflects the renal clearance of Gd-DTPA; and
(a1þa2)
 1¼16.62kgl
 1 represents the plasma volume of the mouse.
Image processing and analysis
Image processing and analysis was performed with programs
written in-house in C and IDL (Research Systems Inc, Boulder, CO,
USA), running on a unix workstation. Region of interest
comprised entire tumour volumes and were defined using the
T2-weighted images to include tumour but exclude surrounding
skin. Time courses for contrast enhancement for each voxel within
the whole tumour were used to produce parametric maps for
analysis using the pharmacokinetic model of Tofts and Kermode
(1991). This allowed voxelwise estimations of the volume transfer
constant for Gd-DTPA between blood plasma and the extravas-
cular extracellular space (K
trans), and of the volume of extra-
vascular extracellular space per unit volume of tissue (VE) (Tofts
et al, 1999). On the basis of their low Gd-DTPA uptake, unfitted
voxels were included in the K
trans maps as zeros.
Statistical analysis of MRI data
Tumour data were analysed both by grouping all values within
treatment groups (t-test) and by comparing mean individual
animal data obtained pre- and post-treatment (paired t-test). The
reproducibility of each pairwise comparison in control animals
was assessed from the test-retest coefficient of variation (CV). For
each subject, i, the CV is the standard deviation, si, for the two
measurements on that subject, divided by the mean volume, mi, for
the subject. The overall test-retest CV for a group of N subjects is
then:
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
X
i
s
mi
   2
=N
v u u t
To address the heterogeneous enhancement in tumours (i.e. a
rapidly enhancing rim and slowly enhancing core), a novel
histogram-based analysis was made by pooling all the K
trans values
from pharmacokinetic model-fitted voxels obtained before and
after treatment for individual mice. A threshold of the top 20% of
values for K
trans was chosen that corresponded visually with
tumour rims (top 20%) and cores (bottom 80%). Changes in the
number of fitted voxels over the 20% threshold pre- and post-
treatment with ZD6474 were calculated on a mouse-by-mouse
basis and examined using a paired t-test. This enabled the effect of
drug treatment on the most rapidly enhancing rim (high K
trans
values) and the slower enhancing core (low K
trans values) to be
examined. The exercise was repeated to examine the ZD6474-
induced changes in the number of voxels below the 20% threshold.
A significance level of 0.05 was used throughout.
RESULTS
Qualitative assessment of DCE-MRI images
An example of a baseline tumour image (single slice), preceding
ZD6474 treatment, is shown in Figure 1 before, and 2 and 10min
after, Gd-DTPA injection. Fast contrast enhancement was observed
in peripheral regions of the tumour. Signal enhancement was
slower in central regions of the tumour, still increasing in some
areas by 11min after Gd-DTPA injection when the collection of
dynamic data was stopped. The effect in the tumour core is
suggestive of an enhancement pattern dominated by diffusion. In
contrast to tumour, muscle of the hind limb was observed to
enhance more uniformly and with loss of signal by the end of the
dynamic run: an observation that is consistent with this tissue
being comparatively well perfused.
DCE-MRI data fitting and reproducibility
A sample kinetic plot of contrast agent concentration for single
voxels (selected at random) in the rim and the core of a tumour are
shown in Figure 2. Curves fitted to the data were generated using
the Tofts and Kermode model. A clear difference in the rate of
initial enhancement was observed, which is consistent with the
qualitative assessment of the DCE-MRI images (i.e. greatest
enhancement in voxels within the tumour rim).
To estimate the reproducibility of the DCE-MRI method, repeat
measurements of 11 vehicle-only-treated control animals were
used. Whole tumours were defined from T2-weighted fast spin-
echo images and time courses for enhancement through the
tumour enabled voxelwise calculation of pharmacokinetic para-
meters. There were no significant differences in repeat measure-
ments of mean K
trans (P¼0.40) or VE (P¼0.10) made on the same
tumour. There was some variability between animals, with inter
animal CVs of 40 and 18% for K
trans and VE, respectively (Table 1).
This was larger than the intra-animal (i.e. test, retest) variability
observed, which gave CVs of 18% for K
trans and 7% for VE. Since
using each animal as its own control reduced variability by more
than 50%, pharmacokinetic data were analysed in this way and
group sizes were significantly reduced.
(ii) 2 min 
(iii) 10 min 
(i) Pre
Figure 1 Sagittal single slice images through the tumour and muscle of
the hind limb. Dynamic contrast-enhanced magnetic resonance imaging
images were acquired before, and 2 and 10min after, injection of the
contrast agent (Gd-DTPA). The tumour rim enhanced rapidly and the core
more slowly. Muscle of the hind limb is located to the right of the tumour.
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During the 2 days of the MRI experiments, there were no effects of
ZD6474 on tumour volumes and no significant change in the
percentage of poorly enhancing areas (i.e. unfitted voxels) that
may reflect the extent of tumor necrosis. The K
trans and VE maps
for matched slices through the centre of a tumour obtained pre-
and postdosing with 50mgkg
 1 of ZD6474 are shown in Figure 3:
reductions in both parameters were evident following compound
treatment. Pooling all pharmacokinetic data from tumours within
a treatment group showed that acute ZD6474 treatment reduced
mean K
trans and VE at all doses examined, with statistical
significance at X25mgkg
 1 for K
trans and X50mgkg
 1 for VE
(Table 2; Figure 4).
Analysis of contrast enhancement using a histogram
analysis
A histogram analysis was carried out in order to highlight any
regional variation in enhancement. Figure 5 shows a histogram of
the K
trans data for a single tumour and illustrates the drug-induced
changes seen. Using the histogram analysis approach described in
the Materials and Methods, significant reductions in K
trans were
seen in both the 20% most-enhancing (rim) and the remaining
least-enhancing (core) parts of tumours (Figure 6). Larger
reductions were seen in the core compared to the rim regions.
Effect of chronic ZD6474 treatment on PC-3 tumour
volume
Chronic once daily oral administration of ZD6474 for 11 days
produced dose-related effects on the growth of well-established
(B1cm
3 volume) PC-3 tumours (Figure 7). Marked regression was
induced in all tumours with 50 and 100mgkg
 1day
 1 ZD6474.
Although the extent of tumour regression induced by 100 and
50mgkg
 1 ZD6474 was similar for the first 7 days of dosing, the
response was significantly different following 11 days of treatment
(P¼0.04, one-tailed t-test), with mean tumour volumes being 70
and 51% smaller, respectively, than their pretreatment volumes. In
contrast, the predominant effect from treatment with 25mgkg
 1
ZD6474 was a reduction in the rate of tumour growth, with
regressions (of 13 and 40%) only being evident in two out of seven
tumours.
DISCUSSION
Inhibition of VEGF signal transduction is being avidly pursued as a
key antiangiogenic strategy, with the potential to constrain or
impede the progression of all solid tumour disease. In addition to
its mitogenic and motogenic effects on endothelial cells, VEGF can
also increase the permeability of vascular endothelium signifi-
cantly (Senger et al, 1990). It may therefore be possible to monitor
changes in vascular permeability in response to anti-VEGF
therapy, before the consequences of an antiangiogenic effect are
apparent. Measures of vascular permeability have been made
previously in preclinical tumour models with DCE-MRI methodol-
ogy and linked to VEGF expression (Bhujwalla et al, 2001, Dafni
et al, 2002; Gossmann et al, 2002). Furthermore, clinical DCE-MRI
measurements of exchange rates in tumours have been found to
correlate with VEGF expression (Knopp et al, 1999).
The DCE-MRI study described here used Gd-DTPA to measure
the dynamic parameter K
trans according to the model of Tofts and
Kermode (1991). K
trans reflects the concentration and flow of
contrast agent in plasma, the tumour vascularity, vascular surface
area, vascular permeability and the size of the extracellular space.
This parameter may therefore be appropriate for measuring
changes that occur in response to treatment with VEGF-signalling
inhibitors. Although low molecular contrast agents have been
suggested to have limitations when measuring vascular perme-
ability (Brasch et al, 2000), K
trans was measured reproducibly using
Gd-DTPA, with intra-animal variability being comparatively low
0 100 200 300 400 500 600
0.00
0.05
0.10
0.15
0.20
P
l
a
s
m
a
 
G
d
-
D
T
P
A
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
m
m
o
l
 
k
g
–
1
)
Time postcontrast injection (s)
Single voxel in core
Single voxel in rim
Figure 2 Plot of the concentration of contrast agent (mmolkg
 1)i n
mouse plasma against time in seconds after the contrast injection, for a
single voxel in the rim and a voxel in the core of the tumour. Curves fitted
to the data were generated using the Tofts and Kermode model. The
respective rim and core K
trans values were 1.9 and 0.71 10
 3s
 1, while VE
values were 0.0660 and 0.0661.
Table 1 Reproducibility of dynamic MRI data
Parameter Variability
a Mean7s.d.
b CV (%)
K
trans Between animals 0.5470.220 40
Within animals 0.5470.080 16
VE Between animals 0.1270.021 18
Within animals 0.1270.008 7
aTwo repeat measurements were made in each of 11 tumour-bearing animals.
bUnit
for K
trans is  10
 3s
 1.
AB
CD
Figure 3 K
trans (A,B) and VE (C,D) maps for matched slices through the
centre of one tumour obtained pre (A,C) and post (B,D) dosing with
50mgkg
 1 of ZD6474. White areas have high values for K
trans or VE. Grey
voxels have low values and black voxels are those that could not be fitted
to the Tofts and Kermode model generally as a result of very slow washin
and washout of contrast during the study period. The white bar in (A)i s
3mm long.
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permeability measurements in patients with solid tumors indicates
that DCE-MRI assessment using Gd-DTPA may be even more
reproducible in man (Jackson et al, 2003).
ZD6474 is a VEGF-signalling inhibitor that has demonstrated
broad-spectrum activity in established tumour xenograft models,
with chronic, once-daily oral administration producing significant
growth delays at doses of 25mgkg
 1day
 1 or less (Wedge et al,
2002). In large, well-established, PC-3 tumour xenografts (B1cm
3
volume), it is possible to induce regression with chronic ZD6474
treatment. This phenomenon is believed to result from the
inhibition of VEGF-signalling alone (Wedge et al, 2002). Since
we have found the PC-3 tumour model to be more highly
permeable than other tumour xenografts (Checkley et al, 2003), it
was selected to explore dose-dependent changes in K
trans.
Dynamic contrast-enhanced magnetic resonance imaging en-
abled an effect on K
trans to be measured before any inhibition of
tumour growth could be detected. Acute dosing of 50 and
100mgkg
 1 ZD6474 produced comparable changes in K
trans
(reduction of B30%), while chronic treatment induced tumour
regressions, with equivalent effects being apparent after 7 days of
dosing. However, 100mgkg
 1 ZD6474 did eventually have a
greater effect on tumour volume, after 11 days of treatment. A
smaller but significant effect on K
trans (reduction of 12.5%) was
apparent following acute treatment with 25mgkg
 1 ZD6474, but
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Figure 4 The percentage reduction in K
trans and VE following the
treatment of PC-3-xenografted tumours with ZD6474 or vehicle. ZD6474
(25–100mgkg
 1) given orally 24 and 2h prior to imaging. Values are
means and s.d. of 6–11 mice. Statistical significance was determined using a
paired t-test.
Table 2 Acute effects of ZD6474: changes in K
trans and VE values pre- and postdosing prostate tumour-bearing mice with ZD6474
Mean K
trans ( 10
 3s
 1)
a Mean VE
a
Dose (mg
 1/kg) No mice Pre Post P Pre Post P
0 11 0.5470.22 0.5270.21 0.4 0.1270.02 0.1170.02 0.1
12.5 6 0.6970.10 0.5870.19 0.1 0.1170.01 0.1070.02 0.09
25 6 0.5670.16 0.4970.17 0.04 0.1270.02 0.1070.01 0.07
50 10 0.7270.19 0.5170.15 0.0005 0.1270.01 0.1070.02 0.0001
100 11 0.6270.18 0.4370.10 0.0004 0.1470.01 0.1170.01 o0.0001
aValues are grouped means with s.d. from all the animals studied.
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Figure 5 Histogram of K
trans data for a single tumour pre- and 24h post-
treatment with 50mgkg
 1 ZD6474. The total numbers of voxels pre- and
post-treatment were 1198 and 1210, respectively. The 20% threshold
value for the tumour illustrated was 0.00155s
 1.
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Figure 6 Significant reductions in K
trans were seen in both the 20% most
enhancing (rim) and the least (core) enhancing parts of tumours. Data from
a single experiment were analysed using a histogram threshold technique to
separate the 20% highest values for K
trans from the remaining values that
corresponded with the tumor rim and core, respectively. Values are means
from 6–11 mice, and statistical significance was determined using a paired
t-test comparing pre- and post-treatment with ZD6474/vehicle.
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chronically administering this dose of ZD6474 was to inhibit the
rate of PC-3 tumour growth. In contrast, acute treatment with
12.5mgkg
 1 ZD6474 did not produce a statistically significant
effect on K
trans or VE. Collectively, these data suggest that in this
tumour model, a relationship exists between the dose of ZD6474
administered, the MRI parameters K
trans and VE (measured after
acute treatment) and the effect on tumour growth (following
chronic dosing).
VE is unlikely to be used to monitor changes in vascular
permeability, but is reported for interest. Since acute exposure to
ZD6474 (50 and 100mgkg
 1) would not be expected to reduce the
volume of the interstitial space significantly, the reductions in VE
observed might be a consequence of significantly reduced vascular
permeability, which could limit contrast agent availability to the
extracellular space. In principle though, VE could increase or
decrease in response to changes in K
trans, and VE is not well
determined where K
trans is low. Indeed, some high values for VE
were observed in the tumour core where K
trans was reduced.
This is the first preclinical study to indicate that dose–response
information vs K
trans can be obtained acutely with a VEGF-
signalling inhibitor, using Gd-DTPA. Small molecular weight
contrast agents have recently been used in two other preclinical
studies to examine the effect on K
trans following inhibition of VEGF
signalling. In the first of these, an antibody to VEGF was
administered to athymic rats bearing small intracranial tumours
(Gossmann et al, 2002). A very significant reduction in K
trans was
measured, although the effect was assessed following three doses of
antibody over the course of a week, and the tumours may have
been more highly perfused given their small size and site of
growth. In the second study, a mixed KDR and Flt-1 tyrosine
kinase inhibitor was assessed at a single dose (50mgkg
 1day
 1)
following chronic administration (21 days) in a murine syngeneic
renal tumour model and a reduction in permeability of
approximately 50% was reported (Drevs et al, 2002a). Interest-
ingly, ZD6474 has also demonstrated a highly significant effect on
tumour growth and metastasis in this particular model (Drevs et al,
2002b). Collectively, these data highlight a growing interest in the
use of clinically applicable contrast agents to measure K
trans and
determine responses following acute treatment with VEGF-
signalling inhibitors.
Analysis of the mean of all voxels within a tumour may not be
optimal for assessing the effectiveness of anti-VEGF therapy using
DCE-MRI, since highly vascular areas could respond differently
from regions containing substantial necrosis. The tumour rim is
known to be highly enhancing, and the centres of tumours are
known to contain variable degrees of necrosis (Marzola et al,
2003). However, methods for analysing groups of K
trans maps are
not well developed and generally manually selected ROI are used.
Examination of the distribution of data using a histogram analysis,
as used in this study, could provide additional information on
intratumour heterogeneity, reduce sampling errors and improve
understanding of the mechanisms behind tumour responses to
treatment. The histogram threshold analysis indicated that,
following ZD6474 treatment, significant reductions in K
trans were
evident in both areas of the tumour, but tumour cores were
affected to a greater extent. Using manually selected ROI in
xenografted human breast tumours, reduced vascular permeability
has been seen to a similar extent in both the tumour rim and its
centre, following administration of an anti-VEGF antibody (Pham
et al., 1998). The disparity between this study and that reported
here may be attributable to differences in anti-VEGF agent, the
method of sampling and analysis, choice of contrast agent, or
simply highlight the potential for model-dependent effects.
In summary, this study suggests that DCE-MRI, using a small
molecular weight contrast agent, could provide a method for
examining permeability changes in response to acute treatment
with an inhibitor of VEGF-signalling. The study also indicates that
a histogram analysis of tumour K
trans data can reveal additional
spatial information of interest.
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